retatrutide clinical trial safety 📈 PHASE 3 RESULTS: BY THE NUMBERS Let's break down what the trials actually showed: SURMOUNT-1 Results (68 weeks): • Average weight loss: 24% of body weight • Participants retatrutide clinical trial information Safety,

Blonde L, Belousova L, Fainberg U, Garcia-Hernandez PA, Jain SM, Kaltoft MS, et al

If you find that exercising after injection consistently triggers nausea, try injecting in a non-exercised body region or adjusting your workout timing relative to injection day

For patients on GLP-1 or GIP/GLP-1 therapy, many endocrinologists and diabetes educators suggest targeting these recommended adequate intake levels, with particular attention to consistent hydration during dose escalation periods when gastrointestinal symptoms are most pronounced

They should generally be avoided in: People with type 1 diabetes People with a history of medullary thyroid cancer (personal or family history) Those with a history of pancreatitis Pregnant or breastfeeding women Always consult your doctor before starting any new medication and we highly recommend Dr